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Abstract
Background: Accurate grading at the time of diagnosis if fundamental to risk stratification and treatment decision
making in patients with prostate cancer. Whilst previous studies have demonstrated significant pathological
upgrading and downgrading following radical prostatectomy (RP), these were based on historical cohorts and do
not reflect contemporary patient selection and management practices. The aim of this national, multicentre
observational study was to characterise contemporary rates and risk factors for pathological upgrading after RP in
the United Kingdom (UK).
Methods: All RP entries on the British Association of Urological Surgeons (BAUS) Radical Prostatectomy Registry
database of prospectively entered cases undertaken between January 2011 and December 2016 were extracted.
Those patients with full preoperative PSA, clinical stage, needle biopsy and subsequent RP pathological grade
information were included. Upgrade was defined as any increase in Gleason grade from initial needle biopsy to
pathological assessment of the entire surgical specimen. Statistical analysis and multivariate logistic regression were
undertaken using R version 3.5 (R Foundation for Statistical Computing, Vienna, Austria).
Results: A total of 17,598 patients met full inclusion criteria. Absolute concordance between initial biopsy and
pathological grade was 58.9% (n = 10,364), whilst upgrade and downgrade rates were 25.5% (n = 4489) and 15.6%
(n = 2745) respectively. Upgrade rate was highest in those with D’Amico low risk compared with intermediate and
high-risk disease (55.7% versus 19.1 and 24.3% respectively, P < 0.001). Although rates varied between year of
surgery and geographical regions, these differences were not significant after adjusting for other preoperative
diagnostic variables using multivariate logistic regression.
Conclusions: Pathological upgrading after RP in the UK is lower than expected when compared with other large
contemporary series, despite operating on a generally higher risk patient cohort. As new diagnostic techniques that
may reduce rates of pathological upgrading become more widely utilised, this study provides an important
benchmark against which to measure future performance.
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Background
Despite first being described over fifty years ago, Gleason
score has stood the test of time and remains one of the
most powerful prognostic indicators in patients undergo-
ing radical treatment with curative intent [1–5]. The Glea-
son grading system was updated in 2005 and again in
2014 following consensus conferences of the International
Society of Urological Pathology (ISUP) [6, 7]. In the more
recent update, the ISUP supported adoption of a validated
Grade Group stratification system ranging from 1 (Glea-
son score ≤ 6) to 5 (Gleason score 9 or 10), to be used in
conjunction with the overall Gleason system in order to
simplify the number of grading categories and facilitate
more accurate stratification of disease [6].
Despite advances in recent years, conventional diag-
nostic pathways employ transrectal ultrasound (TRUS)
guided prostate biopsy to acquire systematic needle bi-
opsies of the prostate, which has recently been shown to
have a sensitivity of only 48% for the diagnosis of ‘clinic-
ally significant’ cancer, defined as Gleason score of at
least 4 + 3 or a maximum core length of at least 6 mm
[8]. Given the heterogeneity of disease it is not surpris-
ing that a significant proportion of cases are upgraded
following radical prostatectomy (RP) compared with the
initial TRUS biopsy [9–11]. This has wide ranging impli-
cations, as it may potentially lead to undertreatment of
those that are undergraded by the initial biopsy, or con-
versely, overtreatment of those that have been overgraded.
Furthermore, upgrading has been associated with adverse
pathological outcomes, such as positive surgical margin
status and biochemical recurrence [12, 13].
Whilst a small number of studies have reported patho-
logical upgrading rates following RP in large patient
populations, these utilised historical cohorts that under-
went surgery prior to 2012 [10, 11]. Furthermore, nei-
ther involved participants from the United Kingdom
(UK), thereby limiting the generalisability of findings to
this patient population and the National Health Service.
This is of particular importance as, owing to differences
in screening practices across Europe and North America,
a relatively high proportion of patients present with ad-
vanced disease at the time of diagnoses in the UK [14–18].
The objective of this large observational study was to
characterise contemporary rates of pathological upgrad-
ing after RP in the UK and identify risk factors for up-
grading within this population.
Methods
Case selection
Data for patients undergoing radical prostatectomy in the
UK were uploaded prospectively by individual surgeons or
institutions onto the British Association of Urological Sur-
geons (BAUS) Radical Prostatectomy Registry database.
All patients that underwent RP between 1st January 2011
and 31st December 2016 were eligible for inclusion.
Patients with missing data for key variables such as pre-
operative Prostate Specific Antigen (PSA), initial biopsy
Gleason grade, clinical T stage or final RP Gleason grade
were excluded, as were those that underwent salvage
surgery.
Pathological assessment
The time from initial biopsy to RP was not recorded in
the database. However, in the UK the National Health
Service Cancer Reform Strategy states that patients diag-
nosed with cancer should receive definitive treatment
within 31 days of the decision to do so. This means that
most patients will have undergone surgery within 1–2
months of the initial biopsy, thereby ameliorating poten-
tial for genuine grade progression between histological
assessment of the biopsy and surgical specimen.
Whilst the exact type of initial prostate biopsy was not
recorded, TRUS guided biopsy utilising an extended
sampling approach was standard practice across the UK
during the study period. All biopsies were evaluated and
reported by a Consultant Pathologist with or without
expertise in urological pathology. Almost all RP speci-
mens were examined and reported by a Consultant
Pathologist with expertise in urological pathology. No
cases were re-reviewed for the purposes of this study. The
primary outcome was upgrading, defined as any increase
in Gleason grade between the initial biopsy and final RP
histology.
Statistical analysis
Continuous variables were reported using mean, median
and range, and categorical variables as percentages. For
unadjusted comparison between upgraded and non-
upgraded cases, Chi-squared and t-tests were used to as-
sess for statistically significant differences in categorical
and continuous variables respectively. Logistic regression
was used to formally determine the association of key
preoperative variables and upgrading, with the odds ratio
for each being reported alongside a 95% confidence
interval and p-value. D’Amico risk category was not
included in the mutually adjusted model, since it is a
composite variable derived from PSA, clinical T-stage
and biopsy Gleason grade (all of which were included in
the model). All analyses were performed in R v3.5 (R
Core Team (2018). R: A language and environment for
statistical computing. R Foundation for Statistical Com-
puting, Vienna, Austria).
Results
Patient demographics
17,598 of 30,424 patients that were entered onto the
registry between 1st January 2011 and 31st December
2016 met full inclusion criteria. Table 1 demonstrates
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the patient and operative characteristics. Mean age and
preoperative PSA were 63.2 years and 10.06 ng/ml re-
spectively. The majority of cases were performed for
D’Amico high risk disease (52.7%; n = 1766), with only
10% (n = 1766) for low risk disease. The proportion of
cases performed each year increased from 2011 to 2016,
owing to both a yearly increase in the number of cases
entered onto the registry together with a reduction in
the number of cases excluded on account of missing
data each year.
Pathological upgrade rates
Absolute concordance between initial biopsy and patho-
logical Gleason grade was 58.9% (n = 10,364), whilst
upgrade and downgrade rates were 25.5% (n = 4489)
and 15.6% (n = 2745) respectively. Table 2 demonstrates
concordance between the initial biopsy and final RP hist-
ology as stratified by ISUP Grade Groups. Concordance
was lowest in those patients with Grade Group 1 and 4
on initial biopsy (39.6 and 25.4% respectively), whilst
highest in those patients with Grade Group 2 (76.6%).
An increase by one ISUP Grade Group (for example,
from Grade Group 1 on initial biopsy to Grade Group 2
on final RP histopathology) constituted the majority of
upgrading events, with 319 (8.2%), 286 (3.4%) and 181
(6.3%) cases being upgraded by two or more Grade
Groups in patients with Grade Group 1, 2 and 3 on ini-
tial biopsy respectively.
Risk factors for pathological upgrading
Table 3 provides the association between patient and
operative characteristics and pathological upgrading. Up-
grading was associated with a higher preoperative PSA
(10.8 ng/ml versus 9.81 ng/ml; p < 0.001) and reduced
over time, with 30.6% of cases being upgraded in 2011
compared with 23.2% in 2016 (Fig. 1a; p < 0.001). Of
note, upgrade rate was highest in those with D’Amico
low risk compared with intermediate and high-risk dis-
ease (Fig. 1b; 55.7% versus 19.1 and 24.3% respectively, P
< 0.001). There was considerable variation in upgrading
between regions, with rates ranging from 13.9% in re-
gion A to 37.9% in region H (Fig. 1c; P < 0.001).
Table 4 gives the results of the mutually adjusted lo-
gistic regression analysis for upgrading. After adjusting
for differences in other characteristics, both increased
age and preoperative PSA were associated with increased
Table 1 Patient, disease and operative characteristics
Patient and disease characteristics
Age (years)
Mean 63.22
Median 64
Range 35–92
Preoperative PSA (ng/ml)
Mean 10.06
Median 7.85
Range 0–181
Preoperative biopsy ISUP Grade Group (%)
1 3914 (22.2)
2 8328 (47.3)
3 2893 (16.4)
4 1427 (8.1)
5 1036 (5.9)
Preoperative clinical stage (%)
T1 5435 (30.9)
T2 8311 (47.2)
T3 3839 (21.8)
T4 13 (0.10
Preoperative D’Amico risk group (%)
Low risk 1766 (10.0)
Intermediate risk 6563 (37.3)
High risk 9269 (52.7)
Operative characteristics
Year of surgery (%)
2011 1001 (5.7)
2012 1159 (6.6)
2013 2259 (12.8)
2014 3783 (21.5)
2015 4566 (25.9)
2016 4830 (27.4)
Region (%)
A 79 (0.4)
B 701 (4.0)
C 1653 (9.4)
D 2081 (11.8)
E 706 (4.0)
F 2084 (11.8)
G 1315 (7.5)
H 29 (0.2)
I 67 (0.4)
J 2093 (11.9)
K 1885 (10.7)
L 1736 (9.9)
Table 1 Patient, disease and operative characteristics
(Continued)
M 745 (4.2)
N 1798 (10.2)
O 324 (1.8)
P 302 (1.7)
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odds of pathological upgrading (OR 1.022; p < 0.001 per
year and OR 1.026; p < 0.001 per ng/ml respectively).
Higher initial biopsy ISUP Grade Groups were associ-
ated with lower odds of upgrading, whilst clinically T2
and T3 tumours had the highest odds of upgrading.
Those cases performed in more recent years were associ-
ated with reduced odds of upgrading when compared
with 2011, although all failed to reach significance. Like-
wise, despite apparent regional differences, almost all
failed to reach significance.
Discussion
This is the largest study to date exploring pathological
upgrading after radical prostatectomy, as well as the first
of its kind conducted within a large contemporary UK
patient cohort. There are several potential reasons for
differences occurring between initial biopsy Gleason
grade and that of the RP specimen. Whilst genuine
grade progression in the time between initial biopsy and
RP is possible, this is unlikely and thus the majority of
discrepancy occurs as a result of either sampling error
or variation in pathological reporting.
Sampling error occurs when an area of high-grade
tumour is missed by the initial needle biopsy, leading to
undergrading. Conversely, the biopsy may oversample
the high-grade component of a tumour. This scenario is
well described, with many studies demonstrating con-
ventional TRUS guided prostate biopsy to be poor at
localising the index tumour and/or estimating true
tumour grade [9–11, 19].
Variation in pathological reporting may result from
the inherent subjectivity of tumour grading, microscopic
interpretation issues and differences in rules used to
report the Gleason score. Tumour grade is a morpho-
logical and biological continuum with arbitrary cut-offs,
so a degree of variation is inevitable in borderline cases.
Microscopic interpretation such as distinction between
poorly formed glands of pattern 4 and tangential sec-
tioning of pattern 3 glands is also subjective [10].
A number of authors have therefore sought to quantify
the level of inter-observer agreement among pathologists
[20, 21], with one recent study demonstrating kappa
values of 0.61 for needle biopsies and 0.37 for RP speci-
mens between the original pathology report and a ‘gold
standard’ report issued by expert urological pathologists
[22]. This study also recognised that the accuracy of
Gleason grading may depend on the level of experience
and training of the reporting pathologist [22]. Whilst the
differing service structure means the findings of many of
these US based studies cannot be completely applied to
the UK, inter-observer variability will no doubt be par-
tially responsible for some of the grade changes seen in
the current series. For example, whilst several cases were
upgraded following RP, a significant number were also
downgraded, most notably from ISUP Grade Group 3 to
2 and from Grade Group 4 to either 3 or 2. In the UK
many initial needle biopsies are reported in smaller Dis-
trict General Hospitals by pathologists who may or may
not have expertise in urological pathology, whilst almost
all RP specimens are reported in larger tertiary referral
centres by expert urological pathologists. It is therefore
possible that some of the observed overcalling of Glea-
son pattern 4 may have arisen due to lack of awareness
among general UK pathologists of the 2014 ISUP con-
sensus conference recommendation that occasional/
seemingly poorly formed or fused glands are insufficient
for a diagnosis of pattern 4 [6]. Finally, even when pa-
thologists agree on the grade, they may report the Glea-
son score differently. For example, when cores show
different Gleason scores, contemporary practice varies
with either the overall (global) or worst Gleason score
recorded for each biopsy series [7, 23, 24].
In this cohort of 17,598 patients we found overall
upgrade and downgrade rates of 25.5 and 15.6% respect-
ively. Interestingly upgrade rate was highest in those pa-
tients undergoing RP for low risk prostate cancer, as
classified using D’Amico criteria that are widely used in
UK practice [25]. Whilst this is somewhat expected
given that this group comprises patients with Gleason 3
+ 3 = 6 disease on initial biopsy, for whom the only
change in grade can be upgrading, the rate of 55.7% is
higher than reported in other comparable series. Whilst
Table 2 Concordance between the initial biopsy and final RP histology when stratified by ISUP Grade Groups
RP ISUP Grade Group Biopsy ISUP Grade Group
1 (≤6) 2 (3 + 4) 3 (4 + 3) 4 (8) 5 (9–10)
No. % No. % No. % No. % No. %
1 (≤6) 1550 39.6 430 5.2 38 1.3 21 1.5 2 0.2
2 (3 + 4) 2045 52.2 6381 76.6 955 33.0 351 24.6 103 9.9
3 (4 + 3) 235 6.0 1231 14.8 1579 54.6 486 34.1 227 21.9
4 (8) 52 1.3 165 2.0 140 4.8 363 25.4 73 7.0
5 (9–10) 32 0.8 121 1.5 181 6.3 206 14.4 631 60.9
Total 3914 100 8328 100 2893 100 1427 100 1036 100
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this may have implications for counselling men with low
risk disease that are considering surveillance, we must
be wary not to extrapolate this figure to all patients. In
the UK, recent years have seen a reduction in the num-
ber of men with low risk disease that undergo radical
treatment [14], which is reflected within our cohort (n =
Table 3 Association between patient, disease and operative characteristics and pathological upgrading after RP
Characteristic No upgrade (n = 13,109) Upgrade (n = 4489) p-value
Age (years) 63.2 (6.56) 63.3 (6.44) 0.159
Preoperative PSA (ng/ml) 9.81 (7.93) 10.8 (8.94) < 0.001
Preoperative biopsy ISUP Grade Group < 0.001
1 1550 (39.6%) 2364 (60.4%)
2 6811 (81.8%) 1517 (18.2%)
3 2572 (88.9%) 321 (11.1%)
4 1213 (85.0%) 214 (15.0%)
5 963 (93.0%) 73 (7.05%)
Preoperative clinical stage < 0.001
T1 3957 (72.8%) 1478 (27.2%)
T2 6350 (76.4%) 1961 (23.6%)
T3 2792 (72.7%) 1047 (27.3%)
T4 10 (76.9%) 3 (23.1%)
Preoperative D’Amico risk group < 0.001
Low risk 782 (44.3%) 984 (55.7%)
Intermediate risk 5307 (80.9%) 1256 (19.1%)
High risk 7020 (75.7%) 2249 (24.3%)
Year of surgery < 0.001
2011 695 (69.4%) 306 (30.6%)
2012 848 (73.2%) 311 (26.8%)
2013 1602 (70.9%) 657 (29.1%)
2014 2835 (74.9%) 948 (25.1%)
2015 3420 (74.9%) 1146 (25.1%)
2016 3709 (76.8%) 1121 (23.2%)
Region < 0.001
A 68 (86.1%) 11 (13.9%)
B 544 (77.6%) 157 (22.4%)
C 1239 (75.0%) 414 (25.0%)
D 1643 (79.0%) 438 (21.0%)
E 552 (78.2%) 154 (21.8%)
F 1536 (73.7%) 548 (26.3%)
G 1020 (77.6%) 295 (22.4%)
H 18 (62.1%) 11 (37.9%)
I 49 (73.1%) 18 (26.9%)
J 1553 (74.2%) 540 (25.8%)
K 1382 (73.3%) 503 (26.7%)
L 1301 (74.9%) 435 (25.1%)
M 505 (67.8%) 240 (32.2%)
N 1246 (69.3%) 552 (30.7%)
O 226 (69.8%) 98 (30.2%)
P 227 (75.2%) 75 (24.8%)
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1766; 10%). This means those patients with low risk dis-
ease that undergo RP are likely to have other ‘high risk’
features, such as large volume tumour.
This study also demonstrated a reduction in upgrading
in more recent years, with the rate falling from 30.6% in
2011 to 23.2% in 2016. Furthermore, we also identified
variation in upgrading between geographical regions,
with rates ranging from 13.9% in region A to 37.9% in
region H. However, when adjusting for differences in
other preoperative variables, almost all differences be-
tween regions and years of surgery failed to reach signifi-
cance. Collectively this means that such differences can
be explained by variation in other factors such as in-
creasing age, preoperative PSA and clinical stage, as well
as decreasing biopsy ISUP Grade Group, all of which
were found to be significant risk factors for upgrading in
our mutually adjusted logistic regression model.
Whilst TRUS guided biopsy utilising an extended sam-
pling approach was standard practice across the UK dur-
ing the study period, the exact biopsy technique utilised
in each case was not recorded in the registry. Recent
years have seen a trend towards increased uptake of pre-
biopsy mpMRI and contemporary diagnostic techniques
such as mpMRI influenced biopsy strategy, template
guided transperineal biopsy and mpMRI-TRUS fusion
biopsy, which have been shown to reduce pathological
upgrading after surgery [26–28]. Furthermore, these
techniques have also been shown to reduce diagnosis of
‘clinically insignificant’ cancers, such as those that are
Gleason 3 + 3 [29]. Collectively this may explain the
trend towards a reduction in upgrading in seen in more
recent years in this series. Furthermore, as these tech-
niques continue to become more widely utilised, future
rates of pathological upgrading are likely to decrease,
thereby rendering this study an important benchmark
against which to measure performance.
A number of other studies have explored upgrading
and downgrading following RP. Whilst many of these
utilised small historical cohorts, the results of the two
largest and most recent series may be compared to the
findings presented here. The first of these, published by
Epstein et al. in 2012, reported grade change in 7643 US
patients that underwent surgery between 2002 and 2010
[10]. Although similar in terms of age, the cohort had a
lower PSA and higher proportion of T1 and Gleason 6
disease, thus representing a lower risk population. Inter-
estingly the authors report an upgrade rate of 36.3%
from Gleason 5–6 to a higher grade after RP, represent-
ing a higher concordance in this group compared with
the present study (63.7% versus 39.6% respectively). The
reasons for these differences are likely multifactorial but
may be due to the small proportion of patients with ini-
tial biopsy Gleason 6 undergoing surgery within our co-
hort, along with the likelihood of this group possessing
Fig. 1 Grade change according to: a, year of surgery. b, D’Amico risk category. c, anonymised region, ranked in order of upgrade rate
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additional high-risk features that would have favoured
this treatment approach. However, despite these differ-
ences, there was agreement that both increasing age and
preoperative PSA were predictors of upgrading [10].
More recently, Danneman et al. reported upgrading
within a cohort of 15,598 patients from the Swedish
National Prostate Cancer Register that underwent RP
between 2000 and 2012 [11]. Inclusion criteria restricted
analysis to patients less than 70 with T1–2 disease and a
serum PSA of < 20 ng/ml, thereby again comprising a
lower risk population than represented here. The au-
thors report an upgrade rate of 35% from Gleason 2–6
to a higher grade after RP, giving a concordance of 65%
in this group. Once again this is much higher than the
present study and may similarly be due to differences in
patient demographics.
The strengths of this study lie in the large cohort and
its origin from a national level data registry. Further-
more, unlike similar studies, all patients were treated
between 2011 and 2016, thereby representing more con-
temporary patient selection and management practices.
This is particularly relevant to the UK, where reducing
numbers of patients with low risk disease are undergoing
radical intervention each year [14].
This study does however have a number of limitations,
including the surgeon/institution reported nature of the
data registry. Although a large proportion of the total
number of patients that undergo RP in UK are entered,
some regions report few numbers and it is possible there
are differences between those patients that are entered
and those that are not. Another limitation is the amount
of missing preoperative data, which led to the exclusion
of a number of cases from the full analysis. This is a
recognised issue with the BAUS Radical Prostatectomy
Registry that must be acknowledged but has not pre-
vented meaningful observations being reported [30, 31].
The type of initial biopsy performed was also unclear, as
was whether the overall or worst Gleason score had been
recorded in each case. However, these scores are differ-
ent in only a minority of cases and previous studies have
demonstrated that both are clinically comparable [32].
Finally, the registry lacked additional pathological pa-
rameters that have previously been linked to risk of
upgrading, including prostate size [10, 12] and extent of
cancer in the biopsy [10, 13].
Conclusions
Pathological upgrading after RP remains an important
consideration in the management of patients with prostate
cancer. This large study demonstrates that overall upgrad-
ing in the UK is lower than expected, with risk factors in-
cluding increasing age, preoperative PSA, and clinical
stage. As new diagnostic techniques that may reduce rates
of pathological upgrading become more widely utilised,
this study will provide an important benchmark against
which to measure performance.
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BAUS: British Association of Urological Surgeons; ISUP: International Society
of Urological Pathology; mpMRI: multi-parametric magnetic resonance
imaging; PSA: Prostate Specific Antigen; RP: Radical prostatectomy;
Table 4 Mutually adjusted logistic regression analysis for
pathological upgrading after RP
Characteristic Odds ratio (95% confidence interval) p-value
Age 1.022 (1.016–1.028) < 0.001
Preoperative PSA 1.026 (1.022–1.031) < 0.001
Preoperative biopsy ISUP Grade Group
1 (reference) 1
2 0.123 (0.112–0.135) < 0.001
3 0.057 (0.049–0.065) < 0.001
4 0.085 (0.072–0.101) < 0.001
5 0.030 (0.023–0.039) < 0.001
Preoperative clinical stage
T1 (reference) 1
T2 1.231 (1.120–1.353) < 0.001
T3 1.990 (1.774–2.232) < 0.001
T4 1.199 (0.275–5.237) 0.809
Year of surgery
2011 (reference) 1
2012 0.930 (0.749–1.156) 0.514
2013 1.084 (0.896–1.311) 0.408
2014 0.851 (0.710–1.021) 0.082
2015 0.935 (0.782–1.118) 0.462
2016 0.908 (0.759–1.086) 0.289
Region
A 0.792 (0.403–1.556) 0.498
B 1.077 (0.857–1.353) 0.526
C 1.071 (0.906–1.265) 0.421
D 0.980 (0.834–1.152) 0.808
E 0.886 (0.704–1.115) 0.303
F 1.152 (0.984–1.348) 0.078
G 0.891 (0.743–1.068) 0.210
H 1.980 (0.840–4.669) 0.118
I 1.299 (0.688–2.452) 0.420
J (reference)a 1
K 0.830 (0.706–0.976) 0.024
L 0.863 (0.731–1.020) 0.084
M 0.837 (0.678–1.033) 0.098
N 1.132 (0.963–1.330) 0.133
O 0.995 (0.741–1.338) 0.976
P 0.654 (0.477–0.897) 0.008
aRegion J chosen as a reference owing to largest number of patients
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